# Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

> **NCT02066402** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 598 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Tedizolid (BAY119-2631)
- **DRUG:** Placebo Tedizolid (BAY119-2631)
- **DRUG:** Linezolid
- **DRUG:** Placebo Linezolid

## Key facts

- **NCT ID:** NCT02066402
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-04
- **Primary completion:** 2016-03-06
- **Final completion:** 2016-04-18
- **Target enrollment:** 598 (ACTUAL)
- **Last updated:** 2017-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02066402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02066402, "Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02066402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*